Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Paranasal Sinus And Nasal Cavity Cancer.

Future Prospects: The future of the Vietnam pharmaceutical drug delivery market is promising. As healthcare needs continue to evolve and drug delivery technologies advance, the demand for efficient ...